{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:10:27Z","timestamp":1789013427183,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Macrophages are critical effectors of antibody therapies for lymphoma, but the best targets to engage their function remain unknown. Here, we develop a \u2018tactical surfaceome profiling\u2019 strategy to define a comprehensive repertoire of surface antigens on B-cell lymphoma that can be targeted with antibodies to provoke macrophage attack. Across both mouse and human systems, we identify multiple unappreciated targets of opsonization as well as putative immune checkpoints. We incorporate this information into a high-throughput engineering strategy, creating 156 bispecific antibodies and identifying dozens that stimulate macrophage-mediated cytotoxicity. A heterodimeric scFv-Fc format enables our approach; it is superior to conventional bispecific antibody design and offers enhanced activity while reducing developmental complexity. Among the therapeutics we create, a bispecific comprising a SIRP\u03b1 decoy domain and a CD38-targeting arm (WTa2d1xCD38) exhibits maximal efficacy with reduced risk of toxicity. This bispecific stimulates robust anti-tumor responses in xenograft models of aggressive B-cell lymphoma and shows benefits over anti-CD20 antibody rituximab. Our approach can be applied to other cancers to leverage anti-tumor responses by macrophages or other immune cells.<\/jats:p>","DOI":"10.1038\/s41467-026-76180-5","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T12:16:24Z","timestamp":1785586584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High-throughput engineering of bispecific antibodies to enhance macrophage-mediated cytotoxicity of B-cell lymphoma"],"prefix":"10.1038","volume":"17","author":[{"given":"Carlota","family":"Pag\u00e8s-Geli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4511-4116","authenticated-orcid":false,"given":"Juliano","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wienclaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Meglan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1315-1302","authenticated-orcid":false,"given":"Lauren","family":"Sloat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Blandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Velarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Vaccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Sebastiany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Fern\u00e1ndez-Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8284-7261","authenticated-orcid":false,"given":"Cynthia K.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7732-7808","authenticated-orcid":false,"given":"Marta","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9008-445X","authenticated-orcid":false,"given":"Kipp","family":"Weiskopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"key":"76180_CR1","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo, E. et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 140, 1229\u20131253 (2022).","journal-title":"Blood"},{"key":"76180_CR2","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","volume":"403","author":"E Silkenstedt","year":"2024","unstructured":"Silkenstedt, E., Salles, G., Campo, E. & Dreyling, M. B-cell non-Hodgkin lymphomas. Lancet 403, 1791\u20131807 (2024).","journal-title":"Lancet"},{"key":"76180_CR3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly, H. et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N. Engl. J. Med. 386, 351\u2013363 (2022).","journal-title":"N. Engl. J. Med."},{"key":"76180_CR4","doi-asserted-by":"publisher","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang, X., Zhu, L., Zhang, H., Chen, S. & Xiao, Y. C. A. R.-T. Cell therapy in hematological malignancies: current opportunities and challenges. Front. Immunol. 13, 927153 (2022).","journal-title":"Front. Immunol."},{"key":"76180_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"76180_CR6","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1182\/blood-2003-07-2365","volume":"103","author":"LM Rimsza","year":"2004","unstructured":"Rimsza, L. M. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and lymphoma molecular profiling project. Blood 103, 4251\u20134258 (2004).","journal-title":"Blood"},{"key":"76180_CR7","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.3324\/haematol.2022.282265","volume":"108","author":"JY Song","year":"2023","unstructured":"Song, J. Y. et al. Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma. Haematologica 108, 2167\u20132177 (2023).","journal-title":"Haematologica"},{"key":"76180_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","volume":"30","author":"FL Locke","year":"2024","unstructured":"Locke, F. L. et al. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T-cell therapy or chemotherapy and transplant in large B-cell lymphoma. Nat. Med. 30, 507\u2013518 (2024).","journal-title":"Nat. Med."},{"key":"76180_CR9","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3324\/haematol.2017.184192","volume":"103","author":"M De Charette","year":"2018","unstructured":"De Charette, M. & Houot, R. Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy. Haematologica 103, 1256\u20131268 (2018).","journal-title":"Haematologica"},{"key":"76180_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41590-017-0004-z","volume":"19","author":"AA Barkal","year":"2018","unstructured":"Barkal, A. A. et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat. Immunol. 19, 76\u201384 (2018).","journal-title":"Nat. Immunol."},{"key":"76180_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3324\/haematol.2014.113472","volume":"100","author":"S Riihijarvi","year":"2015","unstructured":"Riihijarvi, S. et al. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica 100, 238\u2013245 (2015).","journal-title":"Haematologica"},{"key":"76180_CR12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","volume":"6","author":"RA Clynes","year":"2000","unstructured":"Clynes, R. A., Towers, T. L., Presta, L. G. & Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6, 443\u2013446 (2000).","journal-title":"Nat. Med."},{"key":"76180_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","volume":"76","author":"K Weiskopf","year":"2017","unstructured":"Weiskopf, K. Cancer immunotherapy targeting the CD47\/SIRP\u03b1 axis. Eur. J. Cancer 76, 100\u2013109 (2017).","journal-title":"Eur. J. Cancer"},{"key":"76180_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao, M. P. et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699\u2013713 (2010).","journal-title":"Cell"},{"key":"76180_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.1238856","volume":"341","author":"K Weiskopf","year":"2013","unstructured":"Weiskopf, K. et al. Engineered SIRP\u03b1 variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341, 88\u201391 (2013).","journal-title":"Science"},{"key":"76180_CR16","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI81603","volume":"126","author":"K Weiskopf","year":"2016","unstructured":"Weiskopf, K. et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J. Clin. Invest. 126, 2610\u20132620 (2016).","journal-title":"J. Clin. Invest."},{"key":"76180_CR17","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","volume":"379","author":"R Advani","year":"2018","unstructured":"Advani, R. et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin\u2019s Lymphoma. N. Engl. J. Med. 379, 1711\u20131721 (2018).","journal-title":"N. Engl. J. Med."},{"key":"76180_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/13543784.2026.2643307","volume":"35","author":"C Pag\u00e8s-Geli","year":"2026","unstructured":"Pag\u00e8s-Geli, C. & Weiskopf, K. Targeting the CD47\/SIRP\u03b1 interaction in cancer: opportunities in non-Hodgkin lymphoma. Expert Opin. Investig. Drugs 35, 265\u2013272 (2026).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"76180_CR19","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819\u2013829 (2016).","journal-title":"N. Engl. J. Med."},{"key":"76180_CR20","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3390\/cancers12071760","volume":"12","author":"AM Cornel","year":"2020","unstructured":"Cornel, A. M., Mimpen, I. L. & Nierkens, S. MHC Class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers 12, 1760 (2020).","journal-title":"Cancers"},{"key":"76180_CR21","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/1078-0432.498.11.2","volume":"11","author":"E Ryschich","year":"2005","unstructured":"Ryschich, E. et al. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. Clin. Cancer Res. J. Am. Assoc. Cancer Res. 11, 498\u2013504 (2005).","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"76180_CR22","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/protein\/9.7.617","volume":"9","author":"JBB Ridgway","year":"1996","unstructured":"Ridgway, J. B. B., Presta, L. G. & Carter, P. \u2018Knobs-into-holes\u2019 engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. Des. Sel. 9, 617\u2013621 (1996).","journal-title":"Protein Eng. Des. Sel."},{"key":"76180_CR23","doi-asserted-by":"publisher","first-page":"884196","DOI":"10.3389\/fonc.2022.884196","volume":"12","author":"YR Thaker","year":"2022","unstructured":"Thaker, Y. R. et al. A novel affinity engineered anti-CD47 antibody with improved therapeutic index that preserves erythrocytes and normal immune cells. Front. Oncol. 12, 884196 (2022).","journal-title":"Front. Oncol."},{"key":"76180_CR24","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1200\/JCO.18.02018","volume":"37","author":"BI Sikic","year":"2019","unstructured":"Sikic, B. I. et al. First-in-human, first-in-class Phase I trial of the anti-cD47 antibody Hu5F9-G4 in patients with advanced cancers. J. Clin. Oncol. 37, 946\u2013953 (2019).","journal-title":"J. Clin. Oncol."},{"key":"76180_CR25","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-06-2184","volume":"67","author":"AR Jazirehi","year":"2007","unstructured":"Jazirehi, A. R., Vega, M. I. & Bonavida, B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res. 67, 1270\u20131281 (2007).","journal-title":"Cancer Res."},{"key":"76180_CR26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1053\/j.seminoncol.2014.08.006","volume":"41","author":"B Bonavida","year":"2014","unstructured":"Bonavida, B. Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance. Semin. Oncol. 41, 667\u2013677 (2014).","journal-title":"Semin. Oncol."},{"key":"76180_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/science.adq4510","volume":"387","author":"A Ghosh","year":"2025","unstructured":"Ghosh, A. et al. Decoding the molecular interplay of CD20 and therapeutic antibodies with fast volumetric nanoscopy. Science 387, eadq4510 (2025).","journal-title":"Science"},{"key":"76180_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06090-8","volume":"9","author":"H-R Kim","year":"2018","unstructured":"Kim, H.-R. et al. T cell microvilli constitute immunological synaptosomes that carry messages to antigen-presenting cells. Nat. Commun. 9, 3630 (2018).","journal-title":"Nat. Commun."},{"key":"76180_CR29","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2001-12-0207","volume":"100","author":"M Ito","year":"2002","unstructured":"Ito, M. et al. NOD\/SCID\/\u03b3cnull mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100, 3175\u20133182 (2002).","journal-title":"Blood"},{"key":"76180_CR30","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/ni1527","volume":"8","author":"K Takenaka","year":"2007","unstructured":"Takenaka, K. et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat. Immunol. 8, 1313\u20131323 (2007).","journal-title":"Nat. Immunol."},{"key":"76180_CR31","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2020008377","volume":"140","author":"LR Schaff","year":"2022","unstructured":"Schaff, L. R. & Grommes, C. Primary central nervous system lymphoma. Blood 140, 971\u2013979 (2022).","journal-title":"Blood"},{"key":"76180_CR32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1182\/asheducation-2007.1.233","volume":"2007","author":"C Bello","year":"2007","unstructured":"Bello, C. & Sotomayor, E. M. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology 2007, 233\u2013242 (2007).","journal-title":"Hematology"},{"key":"76180_CR33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/antib9040064","volume":"9","author":"R Liu","year":"2020","unstructured":"Liu, R., Oldham, R., Teal, E., Beers, S. & Cragg, M. Fc-Engineering for modulated effector functions\u2014improving antibodies for cancer treatment. Antibodies 9, 64 (2020).","journal-title":"Antibodies"},{"key":"76180_CR34","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.clml.2018.12.013","volume":"19","author":"G Salles","year":"2019","unstructured":"Salles, G. et al. Phase 2 study of daratumumab in relapsed\/refractory mantle-cell lymphoma, diffuse large B-Cell lymphoma, and follicular lymphoma. Clin. Lymphoma Myeloma Leuk. 19, 275\u2013284 (2019).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"76180_CR35","doi-asserted-by":"publisher","unstructured":"Pag\u00e8s-Geli, C. et al. Immune evasion in primary central nervous system lymphoma: macrophage and T cell roles in response to immunotherapy. Haematologica https:\/\/doi.org\/10.3324\/haematol.2025.300015 (2026).","DOI":"10.3324\/haematol.2025.300015"},{"key":"76180_CR36","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1182\/blood-2011-01-333682","volume":"118","author":"E Calpe","year":"2011","unstructured":"Calpe, E. et al. ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1\/2 activation. Blood 118, 4401\u20134410 (2011).","journal-title":"Blood"},{"key":"76180_CR37","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nbt.1562","volume":"27","author":"D Hockemeyer","year":"2009","unstructured":"Hockemeyer, D. et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat. Biotechnol. 27, 851\u2013857 (2009).","journal-title":"Nat. Biotechnol."},{"key":"76180_CR38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI169315","volume":"134","author":"K Vaccaro","year":"2024","unstructured":"Vaccaro, K. et al. Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction. J. Clin. Investig. 134, e169315 (2024).","journal-title":"J. Clin. Investig."},{"key":"76180_CR39","doi-asserted-by":"publisher","first-page":"113023","DOI":"10.1016\/j.celrep.2023.113023","volume":"42","author":"VV Phadnis","year":"2023","unstructured":"Phadnis, V. V. et al. MMD collaborates with ACSL4 and MBOAT7 to promote polyunsaturated phosphatidylinositol remodeling and susceptibility to ferroptosis. Cell Rep. 42, 113023 (2023).","journal-title":"Cell Rep."},{"key":"76180_CR40","doi-asserted-by":"publisher","first-page":"51238","DOI":"10.18632\/oncotarget.17228","volume":"8","author":"F Sun","year":"2017","unstructured":"Sun, F. et al. Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design. Oncotarget 8, 51238\u201351252 (2017).","journal-title":"Oncotarget"},{"key":"76180_CR41","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.1158\/0008-5472.CAN-16-3292","volume":"77","author":"A Dongre","year":"2017","unstructured":"Dongre, A. et al. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res. 77, 3982\u20133989 (2017).","journal-title":"Cancer Res"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76180-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76180-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76180-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:03:29Z","timestamp":1786971809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76180-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76180"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76180-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CPG, JR, KV, AMM, and KW are inventors on US patents and applications pertaining to macrophage-directed therapies for cancer, including PCT\/US2025\/034253 \u201cAntibody Combinations for Macrophage Stimulation\u201d (pending; Whitehead Institute, applicant) which is directly related to this work. KV is a former employee and equity owner of DEM Biopharma. MC has received research funding from Janssen, Genentech and AstraZeneca. KW reports patents\/royalties (Stanford University, Whitehead Institute, Forty Seven, Gilead Sciences, ALX Oncology, DEM Biopharma, Bitterroot Bio, Inograft); co-founder, past or present scientific advisory board member, and equity holder (ALX Oncology, DEM Biopharma, Solu Therapeutics), stock ownership (Ginkgo Bioworks, Inograft). The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8491"}}